IceCure Medical (NASDAQ:ICCM) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS

IceCure Medical (NASDAQ:ICCM) posted its quarterly earnings data on Thursday. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01), Zacks reports. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.07 million.

IceCure Medical Stock Performance

NASDAQ ICCM traded down $0.03 during trading hours on Friday, reaching $1.08. 50,136 shares of the company were exchanged, compared to its average volume of 519,411. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $59.94 million, a P/E ratio of -3.72 and a beta of 0.37. IceCure Medical has a 1 year low of $0.48 and a 1 year high of $1.66. The business’s 50 day simple moving average is $1.32 and its 200-day simple moving average is $0.98.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.50 price target on shares of IceCure Medical in a research report on Friday.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.